|
|
Blood, 15 March 2005, Vol. 105, No. 6, pp. 2535-2542.
Prepublished online as a Blood First Edition Paper on November 30, 2004; DOI 10.1182/blood-2004-09-3701.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line
Ingo Melzner,
Alexandra Juliana Bucur,
Silke Brüderlein,
Karola Dorsch,
Cornelia Hasel,
Thomas F. E. Barth,
Frank Leithäuser, and
Peter Möller
From the Department of Pathology, University of Ulm, Germany.
Primary mediastinal B-cell lymphoma (PMBL) is a well-defined subtype of diffuse large B-cell lymphoma. Molecular cytogenetics revealed frequent gains of 9p24. JAK2, mapping in this region, is presently regarded as a candidate oncogene because expression profiling showed high Janus kinase-2 (JAK2) transcript levels and JAK2 was found to be constitutively phosphorylated in mediastinal B-cell lymphomas. We confirm that in the MedB-1 mediastinal B-cell line, harboring a trisomy 9, JAK2 transcription is elevated and the product is highly phosphorylated. However, JAK2 is not overexpressed at the protein level. On top, JAK2 protein turnover is even delayed. This unexpected finding coincides with a biallelic mutation of the suppressor of cytokine signaling-1 (SOCS-1) gene in this cell, which abrogates SOCS box function of the protein. Ectopic expression of wild-type (wt) SOCS-1 in MedB-1 leads to growth arrest and dramatic reduction of phospho-JAK2 and its downstream partner phospho–signal transducer and activator of transcription-5 (phospho-STAT5). Ultimately, the target gene cyclin D1 is repressed in transfectants while RB1, which is silenced in MedB-1, is induced. We conclude that, in MedB-1, action of phospho-JAK2 is sustained due to defective SOCS-1. Hence, SOCS-1 qualifies as a novel tumor suppressor. Of note, SOCS-1 mutations are also present in the parental tumor of MedB-1 and were detected in 9 of 20 PMBLs.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Holes in SOCS in primary mediastinal large B-cell lymphoma
- Elias Campo
Blood 2005 105: 2244-2245.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. Mottok, C. Renne, K. Willenbrock, M.-L. Hansmann, and A. Brauninger
Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6
Blood,
November 1, 2007;
110(9):
3387 - 3390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Shipp
Molecular Signatures Define New Rational Treatment Targets in Large B-Cell Lymphomas
Hematology,
January 1, 2007;
2007(1):
265 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Mestre-Escorihuela, F. Rubio-Moscardo, J. A. Richter, R. Siebert, J. Climent, V. Fresquet, E. Beltran, X. Agirre, I. Marugan, M. Marin, et al.
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas
Blood,
January 1, 2007;
109(1):
271 - 280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Roberts, G. Wright, A. R. Rosenwald, M. A. Jaramillo, T. M. Grogan, T. P. Miller, Y. Frutiger, W. C. Chan, R. D. Gascoyne, G. Ott, et al.
Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival
Blood,
July 1, 2006;
108(1):
311 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Weniger, I. Melzner, C. K. Menz, S. Wegener, A. J. Bucur, K. Dorsch, T. Mattfeldt, T. F.E. Barth, and P. Moller
Mutations of the Tumor Suppressor Gene SOCS-1 in Classical Hodgkin Lymphoma Are Frequent and Associated with Nuclear Phospho-STAT5 Accumulation.
Blood (ASH Annual Meeting Abstracts),
November 16, 2005;
106(11):
19 - 19.
[Abstract]
|
|
|
|
|
|
|
R. L. Levine, M. Loriaux, B. J. P. Huntly, M. L. Loh, M. Beran, E. Stoffregen, R. Berger, J. J. Clark, S. G. Willis, K. T. Nguyen, et al.
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
Blood,
November 15, 2005;
106(10):
3377 - 3379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos
Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6351 - 6357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi and D. G. Gilliland
The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis
Mayo Clin. Proc.,
July 1, 2005;
80(7):
947 - 958.
[Abstract]
[PDF]
|
|
|
|
|
